Download PDF
Drug Res (Stuttg) 2021; 71(04): 213-218
DOI: 10.1055/a-1275-0228
Original Article

Therapeutic Approach against 2019-nCoV by Inhibition of ACE-2 Receptor

Gajendra Kumar 
1   Department of Chemistry, Krishna College, Bijnor, Uttar Pradesh, India
,
Dharmendra Kumar
2   Science Branch, Archeological Survey of India, Patna Zone, Behar, India
,
Netra Pal Singh
3   Department of Chemistry, Deen Dayal Upadhyaya Gorakhpur University, Gorakhpur, Uttar Pradesh, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

The continued spread of 2019-nCoV has prompted widespread concern around the world. WHO formally named COVID-19 and International Committee on Taxonomy called it Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Due to this viral attack, the whole world is in lockdown. Presently, there is no effective way to control it, except social distancing and hygienic activity. World class scientists and researchers are trying to make vaccine and discover the medicine against the control and cure to this deadly viral disease. Our aim to presenting this article is kick-off deadly viral disease i.e COVID-19 by an easy way with minimum intervention and effort. Different ayurvedic therapeutic agents (Curcuma Longa L, Green tea and Piper nigrum) inhabit entry of virus in host cell, transmission of pathogen and improve the immunity. Curcumin and piperine (1-piperoylpiperidine) interact to each other and form a π—π intermolecular complex which enhance the bioavailability of curcumin by inhibition of glucuronidation of curcumin in liver. Both the molecules curcumin and catechin get bound directly to receptors binding domain of S-protein and ACE-2 receptors of host cell, due to which these molecules inhibit the entry of virus in host cell i. e. animal survives from being infected.

Key words

antiviral drug - 2019 nCoV - curcumin - catechin - 1-piperoylpiperidine - ACE-2 inhibitor


Publication History

Received: 04 September 2020

Accepted: 28 September 2020

Article published online:
12 November 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Cyranoski David. Profile of a scientists are quickly piecing together how the new coronavirus operates, where it came from and what it might do next — but pressing questions remain. Nature 2020; 581: 22-26
    CrossrefPubMedGoogle Scholar
  • 2 Liying D, Shashu H, Jianjun G. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discoveries & Therapeutics 2020; 14: 58-60
    CrossrefPubMedGoogle Scholar
  • 3 Zhou P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; DOI: 10.1038/s41586-020-2012-7.
    CrossrefPubMedGoogle Scholar
  • 4 Rolling updates on corona virus disease (COVID-19) https://www.who.int/emergencies/diseases/novel-coronavirus-019/events-as-they-happen
    PubMed
  • 5 Pengfei S, Xiaosheng L, Chao X. et al. Understanding of COVID-19 based on current evidence. Jou Med Virol 2020; DOI: 10.1002/jmv.25722..
    CrossrefPubMedGoogle Scholar
  • 6 Shulla A, Sargent TH, Subramanya G. et al. Transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J of Virology 2011; 85: 873-882
    CrossrefPubMedGoogle Scholar
  • 7 Shiv K, Roop K, Mohammad M. et al. Turmeric (Curcuma longa L.): A promising spice for phytochemical and pharmacological activitie. International Journal of Green Pharmacy 2013; 7: 85
    CrossrefPubMedGoogle Scholar
  • 8 Priya NC, Kumar PS. Antiviral activities and cytotoxicaty assay of seed extracts of Piper longum and Piper nigrum on human cell lines. Int J Pharm Sci Rev Res 2017; 44: 197-202
    PubMedGoogle Scholar
  • 9 Joshi DR, Shrestha AC, Adhikari N. A Review on diversified use of the king of spices: Piper Nigrum (Black Paper). IJPSR 2018; 9: 4089-4101
    PubMedGoogle Scholar
  • 10 Liu Cynthia, Qiongqiong Z, Yingzhu L. et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent Sci 2020; 6: 315-331
    CrossrefPubMedGoogle Scholar
  • 11 Zheng YY, Ma YT, Zhang JY. et al. COVID-19 and the cardiovascular system. DOI: 10.1038/s41569-020-0360-5.
    CrossrefPubMedGoogle Scholar
  • 12 Firas A, Mazhar S, Al Z. et al. SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far. Pathogens 2020; DOI: 10.3390/pathogens9030231.
    CrossrefPubMedGoogle Scholar
  • 13 Joong SS, Jin HK, Hyun YC. et al. Irreversible Inhibition of CD13/Aminopeptidase N by the Antiangiogenic Agent Curcumin. Chemistry & Biology 2003; 10: 695-704
    CrossrefPubMedGoogle Scholar
  • 14 Reguera J. Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies. PLoSPathog 2012; DOI: 10.1371/journal.ppat.1002859.
    CrossrefPubMedGoogle Scholar
  • 15 Li Fang. Structure, Function, and Evolution of CoronavirusSpike Proteins. Annu Rev Virol 2016; 3: 237-261
    CrossrefPubMedGoogle Scholar
  • 16 Aleksi S, Kvetoslava V, Petr B. et al. Quaternary Benzo[c]phenanthridine Alkaloidsas Inhibitors of Aminopeptidase N andDipeptidyl Peptidase IV. Phytother Res 2002; 16: 84-87
    CrossrefPubMedGoogle Scholar
  • 17 Thomas MG, Michal JB. Coronavirus spike proteins in viral entry and pathogenesis. Virology 2002; 279: 371-374
    PubMedGoogle Scholar
  • 18 Lingshu W. et al. Evaluation candidate vaccine approaches for MERS-CoV. Nature. Communications 2015; 6: 7712 DOI: 10.1038/ncomms8712.
    CrossrefPubMedGoogle Scholar
  • 19 Kenneth EB, Zakir KJ, Duo YC. et al. Angiotensin-converting enzyme in innate and adaptive immunity”. Nat Rev Nephrol 2018; 14: 325-336
    CrossrefPubMedGoogle Scholar
  • 20 Emily LC, Eng EO, Chin YL. et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerging Infectious Diseases 2004; 10: 581-586
    CrossrefPubMedGoogle Scholar
  • 21 Shobal G, david J, Thangam J. et al. Influence of piperine on the pharmacokinetics of curcuminin animals and human volunteers. Planta Medica 1998; 64: 353-356
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Atala BJ, Namrata K, Vinayak N. et al. Catechin and Curcumin interact with corona (2019-nCoV/SARS-CoV2) viral S protein and ACE2 of human cell membrane: Insights from Computational study and implication for intervention. 2020; DOI: 10.21203/rs.3.rs-22057/v1.
    CrossrefPubMedGoogle Scholar
  • 23 Song JM. Anti-infective potential of catechins and their derivatives against viral hepatitis. ClinExp Vaccine Res 2018; 7: 37-42
    CrossrefPubMedGoogle Scholar
  • 24 Shinojima N, Yokoyama T, Kondo Y. et al. Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin induced. Autophagy, Autophogy 2007; 3: 635-637
    CrossrefPubMedGoogle Scholar
  • 25 Vaishali MP, Sukanya D, Krishnan B. Quantum chemical and docking insights into bioavailability enhancement of curcumin by piperine in pepper. J of Phy Chem A 2016; 120: 3643-3653
    CrossrefPubMedGoogle Scholar